| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Bashaier Al-Zaid, Siby Chacko, Charles Ifeamalume Ezeamuzie, Moritz Bünemann, Cornelius Krasel, Tina Karimian, Peter Lanzerstorfer, Suleiman Al-Saba. Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells. Pharmacology research & perspectives. vol 10. issue 5. 2022-09-30. PMID:36177761. |
the incretin hormones: glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) are important regulators of many aspects of metabolism including insulin secretion. |
2022-09-30 |
2023-08-14 |
Not clear |
| Pierpaolo Falcetta, Francesca Nicolì, Fabrizia Citro, Annamaria Ciccarone, Monia Garofolo, Stefano Del Prato, Cristina Bianch. De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes. Acta diabetologica. 2022-09-27. PMID:36166172. |
de-intensification of basal-bolus insulin regimen after initiation of a glp-1 ra improves glycaemic control and promotes weight loss in subjects with type 2 diabetes. |
2022-09-27 |
2023-08-14 |
human |
| Pierpaolo Falcetta, Francesca Nicolì, Fabrizia Citro, Annamaria Ciccarone, Monia Garofolo, Stefano Del Prato, Cristina Bianch. De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes. Acta diabetologica. 2022-09-27. PMID:36166172. |
to evaluate the impact of adding a glucagon-like peptide-1 receptor agonist (glp-1 ra) in people with type 2 diabetes (t2d) in basal-bolus (bb) insulin regimen, on insulin requirement, hba1c, weight loss up to 24 months. |
2022-09-27 |
2023-08-14 |
human |
| Giuseppe Lisco, Anna De Tullio, Olga Disoteo, Vincenzo De Geronimo, Giuseppina Piazzolla, Giovanni De Pergola, Vito Angelo Giagulli, Emilio Jirillo, Edoardo Guastamacchia, Carlo Sabbà, Vincenzo Triggian. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis. Frontiers in endocrinology. vol 13. 2022-09-26. PMID:36157450. |
herein, we overviewed the role of gip and glp-1 in the pathophysiology of type 2 diabetes and systematically reviewed the efficacy and safety of injectable incretin-based therapy added to basal insulin in light of the results of the surpass-5 trial. |
2022-09-26 |
2023-08-14 |
Not clear |
| Giuseppe Lisco, Anna De Tullio, Olga Disoteo, Vincenzo De Geronimo, Giuseppina Piazzolla, Giovanni De Pergola, Vito Angelo Giagulli, Emilio Jirillo, Edoardo Guastamacchia, Carlo Sabbà, Vincenzo Triggian. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis. Frontiers in endocrinology. vol 13. 2022-09-26. PMID:36157450. |
glp-1 receptor agonists (glp-1ras) or tirzepatide added to basal insulin than rigorously titrated basal insulin significantly ameliorates glucose control (Δ hba |
2022-09-26 |
2023-08-14 |
Not clear |
| Shiau Chin Chong, Norlela Sukor, Sarah Anne Robert, Kim Fong Ng, Nor Azmi Kamaruddi. Fasting and stimulated glucagon-like peptide-1 exhibit a compensatory adaptive response in diabetes and pre-diabetes states: A multi-ethnic comparative study. Frontiers in endocrinology. vol 13. 2022-09-26. PMID:36157456. |
the association between total glp-1 levels, insulin resistance, and insulin sensitivity, and glp-1 predictors were also analyzed. |
2022-09-26 |
2023-08-14 |
Not clear |
| Aleksey M Krasnyi, Alsu A Sadekova, Tatyana Y Smolnova, Vyacheslav V Chursin, Natalya A Buralkina, Vladimir D Chuprynin, Ekaterina Yarotskaya, Stanislav V Pavlovich, Gennadiy T Sukhik. The Levels of Ghrelin, Glucagon, Visfatin and Glp-1 Are Decreased in the Peritoneal Fluid of Women with Endometriosis along with the Increased Expression of the CD10 Protease by the Macrophages. International journal of molecular sciences. vol 23. issue 18. 2022-09-23. PMID:36142272. |
the aim of this study was to evaluate the levels of ten energy metabolism factors: c-peptide, ghrelin, gip, glp-1, glucagon, insulin, leptin, pai-1 (total), resistin, and visfatin, and to determine the expression of glp1r receptors, cd10, cd26 proteases, and pro-inflammatory marker cd86 by macrophages in the peritoneal fluid (pf) in patients with endometriosis. |
2022-09-23 |
2023-08-14 |
Not clear |
| Ananyaa Sridhar, Dawood Khan, Mahmoud Abdelaal, Jessie A Elliott, Violetta Naughton, Peter R Flatt, Carel W Le Roux, Neil G Docherty, Charlotte R Moffet. Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats. PloS one. vol 17. issue 9. 2022-09-22. PMID:36137097. |
insulin, glucagon, somatostatin, pyy, glp-1 and gip expression patterns were assessed using immunocytochemistry and analyzed using imagej. |
2022-09-22 |
2023-08-14 |
rat |
| Chirag Jain, Ansarullah, Sara Bilekova, Heiko Licker. Targeting pancreatic β cells for diabetes treatment. Nature metabolism. 2022-09-21. PMID:36131204. |
we describe currently available therapies and their mode of action, as well as insufficiencies of glucagon-like peptide 1 (glp-1) and insulin therapies. |
2022-09-21 |
2023-08-14 |
Not clear |
| Kento Mio, Reina Ogawa, Natsuki Tadenuma, Seiichiro Ao. Arabinoxylan as well as β-glucan in barley promotes GLP-1 secretion by increasing short-chain fatty acids production. Biochemistry and biophysics reports. vol 32. 2022-09-20. PMID:36123993. |
we conducted oral glucose tolerance test (ogtt) to measure insulin and glp-1 concentrations. |
2022-09-20 |
2023-08-14 |
mouse |
| Wang Shin Lei, Marissa J Kilberg, Babette S Zemel, Ronald C Rubenstein, Clea Harris, Saba Sheikh, Andrea Kelly, Joseph M Kindle. Bone metabolism and incretin hormones following glucose ingestion in young adults with pancreatic insufficient cystic fibrosis. Journal of clinical & translational endocrinology. vol 30. 2022-09-16. PMID:36110921. |
gut-derived incretin hormones, including glucose-dependent insulinotropic peptide (gip) and glucagon-like peptide 1 (glp-1), regulate post-prandial glucose metabolism by promoting insulin production. |
2022-09-16 |
2023-08-14 |
Not clear |
| Wang Shin Lei, Marissa J Kilberg, Babette S Zemel, Ronald C Rubenstein, Clea Harris, Saba Sheikh, Andrea Kelly, Joseph M Kindle. Bone metabolism and incretin hormones following glucose ingestion in young adults with pancreatic insufficient cystic fibrosis. Journal of clinical & translational endocrinology. vol 30. 2022-09-16. PMID:36110921. |
gip, glp-1, and insulin contribute to the acute bone anti-resorptive effect of macronutrient ingestion by modifying bone turnover. |
2022-09-16 |
2023-08-14 |
Not clear |
| Yolanda Diz-Chaves, Zainab Mastoor, Carlos Spuch, Lucas C González-Matías, Federico Mall. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. International journal of molecular sciences. vol 23. issue 17. 2022-09-09. PMID:36076972. |
the glucagon-like peptide-1 (glp-1) is a pleiotropic hormone well known for its incretin effect in the glucose-dependent stimulation of insulin secretion. |
2022-09-09 |
2023-08-14 |
Not clear |
| Simona Amodeo, Luigi Mirarchi, Aurelio Seidita, Roberto Citarrella, Anna Licata, Maurizio Soresi, Juan Lucio Iovanna, Lydia Giannitrapan. EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy? International journal of molecular sciences. vol 23. issue 17. 2022-09-09. PMID:36077515. |
agonists of gut-derived glucagon-like peptide-1 (glp-1), gastrointestinal hormones able to increase insulin secretion in response to hyperglycaemia (incretins), have been recently introduced in t2dm therapy, quickly entering the international guidelines. |
2022-09-09 |
2023-08-14 |
Not clear |
| Bozhidar-Adrian Stefanov, Maysam Mansouri, Ghislaine Charpin-El Hamri, Martin Fussenegge. Sunlight-Controllable Biopharmaceutical Production for Remote Emergency Supply of Directly Injectable Therapeutic Proteins. Small (Weinheim an der Bergstrasse, Germany). 2022-09-09. PMID:36084222. |
to illustrate the versatility of this approach, it is shown that not only insulin, but also glucagon-like peptide 1 (glp-1), nanoluciferase (nluc), and the model biopharmaceutical erythropoietin (epo) can be trigger-inducibly released, even when using biologically inactive insulin as a carrier. |
2022-09-09 |
2023-08-14 |
Not clear |
| Agnieszka Baranowska-Bi. Therapy of obesity in women with PCOS using GLP-1 analogues - benefits and limitations [Terapia otyłości u kobiet z PCOS przy zastosowaniu analogów GLP-1 - korzyści i ograniczenia]. Endokrynologia Polska. vol 73. issue 3. 2022-09-05. PMID:36059178. |
the result of the glp-1 therapy is not only a reduction of body weight but also an improvement in insulin resistance and a decrease in hyperandrogenaemia. |
2022-09-05 |
2023-08-14 |
Not clear |
| Agnieszka Baranowska-Bi. Therapy of obesity in women with PCOS using GLP-1 analogues - benefits and limitations [Terapia otyłości u kobiet z PCOS przy zastosowaniu analogów GLP-1 - korzyści i ograniczenia]. Endokrynologia Polska. vol 73. issue 3. 2022-09-05. PMID:36059178. |
this review summarizes and discusses findings regarding obesity and its relation to hyperandrogenism and insulin resistance in pcos, with special attention paid to the pharmacological treatment of adiposity with glp-1 analogues. |
2022-09-05 |
2023-08-14 |
Not clear |
| Federica Ferrari, Antonio Moretti, Roberto Federico Vill. Incretin-based drugs as potential therapy for neurodegenerative diseases: Current status and perspectives. Pharmacology & therapeutics. 2022-09-05. PMID:36064147. |
however, the adverse effects of chronic insulin prompted the research of alternative strategies, such as the novel antidiabetic drugs based on the incretin hormones glucagon-like protein-1 (glp-1) and glucose-dependent insulinotropic peptide (gip). |
2022-09-05 |
2023-08-14 |
Not clear |
| Morgan Jervis, Antonine Pineau Mitchell, Nafseen Islam, Omar G Mustafa, Philip A Kelly, Martin B Whyt. GLP-1 receptor agonist use during hospitalisation: BETTER GLYCAEMIC CONTROL COMPARED TO PRE-MIXED INSULIN. Diabetes/metabolism research and reviews. 2022-09-02. PMID:36052434. |
glp-1 receptor agonist use during hospitalisation: better glycaemic control compared to pre-mixed insulin. |
2022-09-02 |
2023-08-14 |
Not clear |
| Michael A Nauck, David A D'Alessi. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular diabetology. vol 21. issue 1. 2022-09-01. PMID:36050763. |
tirzepatide is an acylated peptide engineered to activate the gip and glp-1 receptors, key mediators of insulin secretion that are also expressed in regions of the brain that regulate food intake. |
2022-09-01 |
2023-08-14 |
human |